Weight Loss Injections

Weight Loss Injections in South Africa: 2026 Buyer's Guide

Key Takeaways

• GLP-1 receptor agonists suppress appetite and slow stomach emptying — they do not burn fat directly
• Registered options cost R2,700–R4,000/month; research peptides cost R1,400–R2,300 per vial but lack regulatory oversight and post-market safety monitoring
• Retatrutide shows the largest weight-loss effect (−24.2% at 48 weeks in Phase 2) but is not yet approved anywhere and carries a smaller safety database than Phase 3 compounds

The Five Injectables at a Glance (SA, 2026)

Injection	Typical SA cost (2025 anchor)
Saxenda (liraglutide)	Registered for obesity [1]	~R3,000–R4,000/month [unverified]
Ozempic (semaglutide)	Registered for T2D; off-label for weight loss [1]	R2,700–R3,100/month [1]
Mounjaro (tirzepatide)	Registered for T2D only [1]	R3,500–R4,000/month [unverified]
Wegovy (semaglutide 2.4 mg)	Not registered [1]	Grey-market only
Retatrutide and research peptides	Not registered [8]	Unregulated

The Short Answer

"Weight loss injections" in South Africa cover two very different categories, and conflating them is how buyers get burned.

Concern: Off-label prescribing of Ozempic and Mounjaro for weight loss means your doctor carries the medico-legal risk if complications arise, and medical aid may not cover the cost under weight-management benefits.

Quick Comparison

Category	Examples	Human Phase 3 evidence	Indicative ZAR/month (2025)
GLP-1 / dual agonist	Saxenda, Ozempic, Mounjaro/tirzepatide	Yes [1][8]	Registered (obesity or T2D) [1]	R2,700–R4,000 [1]
Research peptides	Ipamorelin, tesamorelin, retatrutide	Phase 2 only or none [8]	Not registered [3]	Grey market

Clenbuterol and yohimbine are not peptides. Clenbuterol is a beta-2 agonist and yohimbine is an alpha-2 antagonist. Both get lumped into "fat loss injection" marketing where they don't belong. Keep those three buckets separate before comparing price or dose.

Comparison Table: GLP-1s vs Research Peptides (2026)

Prices are indicative ZAR cash prices from 2025 reporting and listed retailers; confirm with the pharmacy before transacting.

Compound	Mechanism	FDA status (2026)	Typical adult dose	Published weight loss	Common side effects	ZAR / month (2025)
Semaglutide (Ozempic / Wegovy)	GLP-1 receptor agonist	Approved (T2D, obesity as Wegovy, CV risk reduction) [13]	Registered for T2D only; Wegovy not registered [1]	0.25 → 2.4 mg weekly SC	~14.9% at 68 weeks in STEP-1 (2021) [8]	Nausea, vomiting, constipation [1]	R2,700–R3,100 [1]
Tirzepatide (Mounjaro / Zepbound)	Dual GIP / GLP-1 agonist	Approved (T2D as Mounjaro, obesity as Zepbound) [14]	Registered for T2D; obesity off-label [1]	2.5 → 15 mg weekly SC	~20.9% at 72 weeks in SURMOUNT-1 (2022) [8]	Nausea, diarrhoea, decreased appetite [8]	R3,500–R4,000 [1]
Liraglutide (Saxenda)	GLP-1 receptor agonist	Approved (obesity, T2D as Victoza) [7]	Only GLP-1 registered for obesity in SA [1]	0.6 → 3.0 mg daily SC	~8% at 56 weeks (SCALE context) [7]	Nausea, injection-site reactions [1]	R3,000–R4,000 [1]
Retatrutide	Triple GLP-1 / GIP / glucagon agonist	Investigational, Phase 3 ongoing [8][10]	Not registered [3]	2–12 mg weekly SC (trial doses) [8]	−24.2% at 48 weeks, 12 mg (Phase 2, 2023) [8]	Nausea, vomiting, dose-dependent GI [8]	Grey market only
Tesamorelin	GHRH analogue (visceral fat)	Approved for HIV-lipodystrophy only [3]	Not registered for weight loss [3]	2 mg daily SC	Visceral fat reduction in HIV; no general obesity Phase 3 [3]	Injection-site reactions, joint pain [3]	Grey market only
Ipamorelin	Growth hormone secretagogue	Not approved for any indication [3]	Not registered [3]	No validated human obesity dose [3]	No published obesity Phase 3 data [3]	Unknown, contamination risk [3]	Grey market only

How GLP-1 Injections Work (Semaglutide, Tirzepatide, Liraglutide)

GLP-1 receptor agonists cause weight loss by reducing how much you eat, not by burning fat. They mimic glucagon-like peptide-1 (GLP-1), a gut hormone released after meals, which slows gastric emptying, dampens hunger signals in the hypothalamus, and improves post-meal insulin response [1]. Food sits in the stomach longer, so you feel full sooner and the brain's appetite drive softens. Caloric deficit still does the work; the injection makes the deficit sustainable by suppressing hunger rather than by increasing energy expenditure.

Semaglutide (Ozempic, Wegovy)

Tirzepatide (Mounjaro, Zepbound)

Liraglutide (Saxenda, Victoza)

Concern: Daily injections reduce adherence compared to weekly options, and the smaller weight-loss effect may disappoint buyers comparing it to tirzepatide or semaglutide.

None of this class melts fat. They make eating less feel sustainable, and the rest is arithmetic.

Research Peptides: Retatrutide, Tesamorelin, Ipamorelin

Retatrutide

Retatrutide is a once-weekly triple agonist hitting GIP, GLP-1, and glucagon receptors, currently in Phase 3 development by Eli Lilly with no approval anywhere as of 2026 [8][12]. Adding the glucagon receptor arm to the GLP-1/GIP backbone is thought to drive higher energy expenditure on top of appetite suppression, which is the working explanation for the large Phase 2 numbers. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported a least-squares mean weight loss of −24.2% at 48 weeks on 12 mg weekly versus −2.1% on placebo, with 83% of participants hitting ≥15% loss and 93% hitting ≥10% [8]. Those are the largest figures seen in any GLP-1-class trial to date. Phase 2 results in roughly 300 people are not the same as a Phase 3 readout, and the safety database is still thin because fewer patients have been exposed for longer periods. Full Phase 3 primary endpoint data had not been peer-reviewed by late 2025 [12]. Anything labelled "retatrutide" for sale online in SA today is grey-market research material, not pharmaceutical-grade product with batch certification you can trust.

Concern: Phase 2 data alone cannot predict Phase 3 outcomes or long-term safety. Buying retatrutide now means accepting a much smaller evidence base than semaglutide or tirzepatide.

Tesamorelin

Ipamorelin

Concern: No clinical obesity data exists for tesamorelin or ipamorelin. Buying either means you are the experiment.

For a current inventory of what's available, browse the weight loss injections category to see what's in stock and at what dose.

Typical Dosing Protocols (Adult Reference Ranges)

Every injectable in the weight loss injections category is titrated upward over weeks, not started at the target dose, to blunt nausea and GI side effects. The table below is reference material from published labels and trial protocols, not a prescription. Final dosing belongs to a registered SA prescriber who knows your history.

Compound	Starting dose	Target / max dose	Frequency	Route	Source
Semaglutide (Wegovy)	0.25 mg/week	2.4 mg/week	Weekly	SC	[13]
Semaglutide (Ozempic, off-label)	0.25 mg/week	1.0–2.0 mg/week	Weekly	SC	[5]
Tirzepatide (Zepbound/Mounjaro)	2.5 mg/week	15 mg/week	Weekly	SC	[14]
Liraglutide (Saxenda)	0.6 mg/day	3.0 mg/day	Daily	SC	[7]
Retatrutide (Phase 2 trial, 2023)	1 mg/week	up to 12 mg/week	Weekly	SC	[10]
Tesamorelin (Egrifta label)	2 mg/day	2 mg/day	Daily	SC	[unverified label dose]
Ipamorelin (research protocols)	200–300 mcg	200–300 mcg, 1–3x/day	Daily, non-clinical	SC	no clinical label exists

How the GLP-1 Titrations Actually Run

Semaglutide and tirzepatide step up roughly every four weeks because this interval lets the body adapt to each dose and allows nausea to settle before the next increase. Wegovy's published schedule moves 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16–20 weeks [13]. Tirzepatide's label runs 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg in 2.5 mg increments at four-week intervals, and most patients hold at 10 or 15 mg [14]. Saxenda is the outlier: daily injection, with weekly 0.6 mg increases until 3.0 mg [7]. The Body Pharm Tirzepatide 30 Pen is sold as research material and is not a substitute for a titration plan a doctor signs off on.

Retatrutide and the Research Peptides

Retatrutide's Phase 2 obesity trial (2023) used weekly doses of 1, 4, 8 and 12 mg, with the 12 mg arm producing −24.2% mean body-weight loss at 48 weeks versus −2.1% placebo [10]. Phase 3 dosing is still being finalised through Lilly's pipeline studies [12]. Tesamorelin has a real label (2 mg daily SC) but it was approved for HIV-associated lipodystrophy, not general fat loss. Ipamorelin has no clinical label at all. Numbers like 200–300 mcg one to three times daily come from bodybuilding and research-chemical forums, not regulator-reviewed studies, and the AMA has specifically warned against treating those protocols as established medicine [1]. A prescriber who will write and supervise the protocol is non-negotiable.

Concern: Self-dosing research peptides without a prescriber's oversight is the highest-risk scenario on this page.

Real-World Cost in ZAR: What You'll Actually Pay

Option	2026 indicative price (ZAR)	Format	Medical-aid reimbursement
Saxenda (liraglutide)	~R3,000–R4,000/month [unverified, 2024–2025]	Pre-filled pen	Registered for obesity [1]	Discovery Health may fund from day-to-day benefits, plan-dependent [1]
Ozempic (semaglutide 1 mg)	~R2,700–R3,100/month [2025] [1]	Pre-filled pen	Registered for T2D only; weight-loss use is off-label [1]	Generally only under diabetes benefits [4][5]
Mounjaro / Zepbound	No consistent SA retail price; imported [unverified]	Pen	Mounjaro registered for T2D, not obesity [1]	Diabetes benefits only [4][5]
HD Labs Semaglutide 10 mg	R1,400 (Beskinny 2026)	Research vial	Not registered; research use	None
HD Labs Retatrutide 10 mg	R1,600 sale (Beskinny 2026)	Research vial	Not registered; investigational [7][12]	None
HD Labs Retatrutide 32 mg	R2,300 (Beskinny 2026)	Research vial	Not registered; investigational	None
Body Pharm Tirzepatide 30 Pen	See current listing	Research pen	Not registered for obesity	None

Why the Price Gap Is Mostly a Regulatory Gap

Concern: Cheaper research peptides may seem like a bargain, but you lose regulatory oversight, post-market surveillance, and prescriber accountability.

Side Effects and Who Should Not Use Them

GLP-1 receptor agonists cause predictable gastrointestinal side effects and carry a boxed warning for thyroid C-cell tumours. Research peptides carry the same theoretical risks plus the unknown of an unregulated supply chain. Before you buy from the weight loss injections category, read this section and then ask a prescriber.

What Wegovy, Ozempic, Saxenda and Mounjaro Can Do to You

The most common adverse effects across semaglutide, liraglutide and tirzepatide are nausea, vomiting, diarrhoea and constipation, usually worst during dose escalation when the body is adjusting to a new hormone level. Less common but more serious risks listed on the Wegovy and Zepbound prescribing information include acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from dehydration, and hypoglycaemia when combined with insulin or sulfonylureas [2][3]. Both semaglutide and tirzepatide carry a boxed warning against use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent C-cell tumour signals [2][3].

Do not use any GLP-1 if you are pregnant, planning pregnancy, breastfeeding, or have had pancreatitis. Tirzepatide can also reduce the efficacy of oral contraceptives, so a barrier method or non-oral contraceptive is advised for four weeks after starting and after each dose increase [3].

What's Different About Research Peptides

Research-grade semaglutide, tirzepatide and retatrutide share the same mechanism-based risks as the branded versions, with one extra problem: no post-marketing surveillance. The AMA flagged in 2024 that compounded and grey-market peptide injections have been linked to dosing errors, bacterial contamination, and unknown excipients, with no MedWatch-equivalent system catching adverse events [10]. Retatrutide itself only has Phase 2 safety data published so far, with full Phase 3 outcomes still pending [1][14].

If you are still considering a research vial like the Body Pharm Tirzepatide 30 Pen, get baseline bloods, screen for MTC/MEN2 family history, and work with a doctor who knows you are using it. Self-prescribing without medical oversight is the worst trade-off on this page.

Concern: Research peptides lack post-market safety monitoring. Adverse events go unreported, and you have no way to know if a batch is contaminated until you inject it.

How to Choose: A Decision Framework

The right injection depends on which constraint is hardest for you: medical risk, cost, or regulatory comfort. Use the table below as a starting filter, then take the three questions to your prescriber.

Your situation	Best-fit option	Why
Want the lowest-risk, evidence-backed route and can afford R2.7k–R3.1k/month [1]	Registered supply chain, pharmacovigilance, prescriber accountability
Established cardiovascular disease + overweight/obesity	SELECT trial (2023) showed ~20% MACE reduction over ~5 years [9]
Type 2 diabetes alongside weight goal	Ozempic or Mounjaro through medical aid diabetes benefit [1]
BMI ≥35 with T2D considering dual agonism	Tirzepatide (Mounjaro) off-label under specialist supervision [1]	SURMOUNT-1 (2022) showed ~20.9% weight loss at 72 weeks [8]
Cost is the binding constraint	Discuss compounded or alternative regimens with a doctor who will monitor you	Self-sourcing without supervision is the worst trade-off
Pregnant, planning pregnancy, breastfeeding, or prior pancreatitis	None of the above	Contraindicated [2][3]

Three Questions to Ask Your Prescriber

1. Will my medical aid cover this, and under which benefit (chronic, day-to-day, or not at all)? Discovery Health has confirmed Saxenda is funded only from day-to-day benefits, not as a PMB [1].
2. What is the titration plan, and what dose are we targeting by month four?
3. What is the exit strategy after 12 months? Do we taper, switch, or maintain, and how do we manage likely weight regain?

FAQ: Weight Loss Injections in South Africa

Question	Short answer
Which weight loss injections are FDA-approved in 2026?	Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda, Victoza). Retatrutide is investigational [10][13][14].
Do peptides burn fat directly?	No. GLP-1s suppress appetite and slow gastric emptying; they don't oxidise fat tissue [1].
Is retatrutide approved in SA?
Are clenbuterol and yohimbine peptides?	No. Clenbuterol is a beta-2 agonist, yohimbine is an alpha-2 antagonist. Neither belongs in the peptide category.
How fast does semaglutide work?	Appetite drops within 1–2 weeks; meaningful weight loss usually shows after 8–12 weeks of titration [5].
Does medical aid cover it?	Discovery Health funds Saxenda from day-to-day benefits, not PMB. Ozempic and Mounjaro for weight loss are generally not covered [5].
What happens when you stop?	Significant weight regain is common within 12 months without a maintenance plan [1].

Can You Stack GLP-1s with Clenbuterol or Other Stimulants?

Don't. Clenbuterol is not registered for human use in South Africa, and stacking a beta-2 agonist with a GLP-1 compounds cardiovascular risk, including arrhythmia and tachycardia. No clinical trial supports the combination, and prescribers I've spoken to in 2025 refuse to monitor it.

Are Oral GLP-1 Alternatives Available in SA?

How Does Retatrutide Compare to Semaglutide on Weight Loss?

Is Buying Research-Grade Tirzepatide Legal for Personal Use?

Will the SELECT Cardiovascular Benefit Apply if I Use Ozempic Off-Label?

The 20% MACE reduction came from semaglutide 2.4 mg (Wegovy) in people with overweight/obesity and established CVD, over ~5 years in SELECT (2023) [13]. Ozempic tops out at 1 mg or 2 mg for diabetes dosing. Extrapolating the CV benefit to lower doses or shorter use is not supported by the trial data.

Which Weight Loss Injection Should I Choose?

Next Steps